October 10, 2019
Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing
Montreal, Canada – October 10, 2019 – Theratechnologies Inc. (“Theratechnologies”or the “Company”) (TSX: TH), a commercial-stage biopharmaceutical company addressing unmet medical needs for people with orphan medical conditions, including those living with HIV, is pleased to announce that, as of today, its common shares will begin trading on the NASDAQ Capital Market under the symbol “THTX”.
“Theratechnologies’ NASDAQ listing is yet another step forward for our Company with growing sales from two commercialized products and a strong pipeline. Over the last five years, we have reached significant milestones and our progress continues. In 2014, we bought back the rights to our first commercialized product, EGRIFTA®. In 2018, we launched Trogarzo® in the US, and just recently obtained its approval in Europe, the second largest pharmaceutical market in the world. We are also aggressively developing our promising pipeline for the treatment of NASH in HIV (non-alcoholic steatohepatitis) and certain types of cancers,” said Luc Tanguay, President and CEO, Theratechnologies Inc.